Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML

References

• Byrd J C, Mrozek K, Dodge R K, Carroll A J, Edwards C G, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336
   PubMed Web of Science ®Google Scholar
• Slovak M L, Kopecky K J, Cassileth P A, Harrington D H, Theil K S, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Secker-Walker L M, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91: 490–501
   PubMed Web of Science ®Google Scholar
• Shi G, Weh H J, Duhrsen U, Zeller W, Hossfeld D K. Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies. Cancer Genet Cytogenet 1997; 96: 58–63
   PubMedGoogle Scholar
• Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottaviani E, et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica 1999; 84: 690–694
   PubMed Web of Science ®Google Scholar
• Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022–2031
   PubMed Web of Science ®Google Scholar
• Jolkowska J, Witt M. The EVI-1 gene—its role in pathogenesis of human leukemias. Leuk Res 2000; 24: 553–558
   PubMed Web of Science ®Google Scholar
• Morishita K, Parganas E, William C L, Whittaker M H, Drabkin H, Oval J, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300 – 400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937–3941
   PubMed Web of Science ®Google Scholar
• Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia 1999; 13: 1639–1645
   PubMed Web of Science ®Google Scholar
• Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243–1248
   PubMed Web of Science ®Google Scholar
• Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 2000; 79: 374–377
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel W E, Wormann B, Schoch C, Fonatsch C, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496–4504
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel W E, Schoch C, Haferlach T, Serve H L, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480–2489
   PubMed Web of Science ®Google Scholar
• H Loeffler, Rastetter, J, Haferlach, T. Atlas of Clinical Hematology. Springer, New york. 2004
   Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, LyonFrance 2001
   Google Scholar
• Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59
   PubMed Web of Science ®Google Scholar
• F Mitelman. ISCN 1995, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel. 1995
   Google Scholar
• Schnittger S, Schoch C, Dugas M. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetic, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukemia. Acta Haematologica 2004; 112: 68–78
   PubMed Web of Science ®Google Scholar